19 research outputs found
Omphalolith: An underdiagnosed entity
Abstract Omphalolith is a rare and underdiagnosed entity due to the accumulation of sebum and keratin in the umbilicus. It usually occurs in the elderly with deep and narrow umbilicus. Early recognition of omphalolith is important to prevent complications, unnecessary investigations, and anxiety. We report herein two new cases of omphalolith
Atypical subepidermal blistering disease following COVIDâ19 vaccination
Atypical bullous disease after COVIDâ19 vaccination
Multiple keratoacanthomas of FergusonâSmith type
Abstract We report a case of a 41âyearâold male patient with no family history, presented with extensive multiple keratoacanthomas with disfiguring scars. The diagnosis of a sporadic form of FergusonâSmith syndrome was made. Treatment with acitretin showed a marked response. Recognizing this syndrome is crucial. Early treatment helps avoid scar formation
Chronic Actinic Dermatitis: Two Patients with Successful Management using Narrowband Ultraviolet B Phototherapy with Systemic Steroids
Background. Chronic actinic dermatitis (CAD) is a debilitating photodermatosis with characteristic clinical, histological and photobiological features (reduced minimal erythema dose: MED). Its management involves various therapeutic approaches, among them there is phototherapy. Efficacy of psoralen ultraviolet therapy (PUVA therapy) was previously demonstrated but there are no current data on the use of narrowband ultra violet B (UVB) therapy (NB-UVB) in CAD. NB-UVB has already been proven to be effective and safe in several other photodermatoses.
Case reports. We report here two dark-skinned patients (skin type IV and V) with CAD, successfully treated with an incremental regimen of NB-UVB phototherapy coupled to a 3 month-course of systemic steroids (1mg/Kg/day).
Conclusion. Our protocol of NB-UVB with steroids seems to be effective for the management of CAD with a good short term safety profile
Traitement du psoriasis par mĂ©thotrexate Ă lâĂšre des biothĂ©rapies : Ă©tude chez 21 patients tunisiens
Introduction. Nous prĂ©sentons ici les rĂ©sultats en terme dâefficacitĂ© et de tolĂ©rance du mĂ©thotrexate administrĂ© chez 21 patients tunisiens atteints de psoriasis sĂ©vĂšre. MĂ©thode. Il sâagit dâune Ă©tude rĂ©trospective menĂ©e, de janvier 2002 Ă dĂ©cembre 2009, au service de dermatologie de lâHĂŽpital Charles Nicolle de Tunis. Nous avons recensĂ© 21 patients atteints de psoriasis sĂ©vĂšre et mis sous mĂ©thotrexate. RĂ©sultats. La moyenne dâĂąge des patients Ă©tait de 53 ans avec un sex-ratio de 6. La durĂ©e moyenne dâĂ©volution du psoriasis Ă©tait de 10 ans (un mois - 60 ans). Il sâagissait dâun psoriasis en plaques dans 18 cas (85,8 %) [surface cutanĂ©e moyenne atteinte de 63 %], dâun psoriasis Ă©rythrodermique dans 2 cas (9,5 %) et dâun psoriasis arthropathique dans 1 cas (4,7 %). Le mĂ©thotrexate a Ă©tĂ© administrĂ© per os Ă une dose initiale de 5 Ă 7,5 mg/semaine. La dose maximale hebdomadaire Ă©tait de 7,5 mg Ă 12,5 mg. La rĂ©mission Ă©tait totale dans 62 % des cas et partielle dans 28,5 % des cas. Des effets indĂ©sirables hĂ©matologiques et hĂ©patiques ont Ă©tĂ© observĂ©s chez 2 patients (9,5 %). La pĂ©riode de rĂ©mission aprĂšs lâarrĂȘt du mĂ©thotrexate Ă©tait en moyenne de 14 mois (3 mois-3 ans). Une rĂ©cidive Ă type de psoriasis sĂ©vĂšre a Ă©tĂ© observĂ©e chez 7 patients. Conclusion. Notre Ă©tude montre une bonne rĂ©ponse clinique du psoriasis sĂ©vĂšre au mĂ©thotrexate et ce en terme de taux et de durĂ©e de rĂ©mission, malgrĂ© des doses hebdomadaires plus faibles que celles classiquement utilisĂ©es dans la littĂ©rature